# Study of BGB-A317 in Participants With Previously Treated Unresectable HCC

> **NCT03419897** · PHASE2 · COMPLETED · sponsor: **BeiGene** · enrollment: 249 (actual)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT03419897
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-09
- **Primary completion:** 2021-06-30
- **Final completion:** 2022-07-06
- **Target enrollment:** 249 (ACTUAL)
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03419897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03419897, "Study of BGB-A317 in Participants With Previously Treated Unresectable HCC". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03419897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*